Skip to main content

Table 2 Trial sequential analysis for overall mortality

From: Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

Relative Risk reduction, %

Control group event rate, %

I2, %

D2, %

RIS

RIS achieved

TSA adjusted RR (95% CI)

Results

Overall analysis (16 studies; n = 2130)

 30%

35%

42

62

2110

-

0.731 (0.595–0.897)

Sig risk reduction

 25%

35%

42

62

3090

-

0.731 (0.563–0.949)

Sig risk reduction

 20%

35%

42

62

4902

43.5%

0.731 (0.532–1.003)

Trend to sig reduction

Subgroup with lower control group mortality (8 studies; n = 1337)

 30%

30%

18

60

2489

53.7%

0.889 (0.605–1.307)

Uncertain

 25%

30%

18

60

3653

36.6%

0.889 (0.560–1.412)

Uncertain

 20%

30%

18

60

5811

23.0%

0.889 (0.496–1.596)

Uncertain

Subgroup with higher control group mortality (8 studies; n = 793)

 30%

45%

0

0

545

–

0.651 (0.530–0.801)

Sig risk reduction

 25%

45%

0

0

793

–

0.651 (0.535–0.793)

Sig risk reduction

 20%

45%

0

0

1251

–

0.651 (0.506–0.839)

Sig risk reduction

  1. DerSimonian–Laird Random effect model, Alpha 5%, beta 10%
  2. RIS required information size, TSA Trial sequential analysis